Introduction
Autologous erythrocyte agglutination test was a kind of whole blood cell agglutination for the assay of antibodies or antigens in the blood. The major characteristic of autologous erythrocyte agglutination test was simple and rapid in the process of blood assay. The results could be obtained within 2-5 min, while the sensitivity and specificity were comparable to enzyme-linked immunosorbent assay (ELISA). So, autologous erythrocyte agglutination test was suitable for the blood assay in emergency patients, high risk individuals and remote area populations.
Initially, the main ingredient of reagent for autologous erythrocyte agglutination test was prepared by chemical conjugation of an anti-human red blood cell (RBC) mAb with a peptide derived from HIV-1 envelope gp41 (1) . But, for chemical methods, it had some problems in the process of preparation and utilization, such as the activity of mAb affected by the chemical reagents and long time of screening the proper molecules. To overcome the deficiencies, chemical conjugation techniques were improved by use of different enzymes, but they still maintained laborious and the yield of the conjugation was lower than expected (2) . Though autologous erythrocyte agglutination test met some problems, it was still a creative design with good perspective, and could be developed for detection of a variety of antigens and antibodies (3) .
Recombinant single chain Fv (ScFv)/Fab (antigen binding fragment) technology brought about the new hope of gaining the fusion protein as the main ingredient of reagent for autologous erythrocyte agglutination test. The advantage of this method was its easiness to get the fusion protein once the expression vector was constructed successfully. An example was then implemented for the preparation of monovalent ScFv fragment of anti-RBC antibody fused to immunodominant peptides derived from envelope glycoproteins gp41 of HIV-1 (4, 5) . Later, for more functions, this group produced a Fab fusion protein carrying immunodominant epitopes of HIV-1 and HIV-2 fused to the C-terminal of Fd and LC in Fab (6) . Recently, a more interesting attempt was to produce a cocktail formulation of reagent ingredient composed of several fusion proteins with different dominant epitopes of HIV (7) . Those fusion proteins consisting of the monovalent Fab of anti-human RBC monoclonal antibody with immunodominant peptides derived from envelope glycoproteins gp41 of HIV-1, HIV-1 capsid protein p24 and gp36 of HIV-2, respectively (8, 9) . In late studies, this group made a single molecule capable of simultaneous detection of both HIV-1 and HIV-2 in a drop of blood (10) . Not only envelope glycoprotein gp41 of HIV-1, but also gp160 of HIV-1 was employed in this field (11) .
Generally, the fusion protein derived from recombinant vector was expressed in E. coli in soluble form. But, the yield of the fusion protein was low because a small quantity of active proteins was released into culture supernatant. For another way to gain target protein, in this study, a recombinant bifunctional molecule (ScFv 2E8 -C H 1-gp41) as the main ingredient of reagent for autologous erythrocyte agglutination test was designed and expressed in E. coli. The fusion protein was gained from the inclusion bodies and kept activity by denaturation and renaturation in vitro. Meanwhile, in mimic test, as the main ingredient of reagent for autologous erythrocyte agglutination test, the bifunctional protein could agglutinate the RBCs in the presence of HIV-1 gp41 antibodies using sera from HIV-infected individuals.
Materials and Methods

Cell line
A hybridoma strain 2E8 secreting monoclonal antibody (mAb 2E8 ) (12) against H antigen on the surface of human erythrocyte was cultivated at 37 o C in 5% CO 2 atmosphere in RPMI 1640 medium with 10% fetal bovine serum, 100 units/ml penicillin G sodium and 100 μg/ml streptomycin sulfate.
Cloning of mAb 2E8 variable region genes by 5' RACE
Total RNA was isolated from 2E8 hybridoma strain using TRIzol reagent (GIBCO) according to the manufacturer's protocol. cDNA was synthesized by extension of Oligo (dT) 15 primer using Superscript TM -II Amplification System (Invitrogen) according to the protocol of manufacturer. The first strand was then poly-G tailed using terminal transferase (Promega). The tailed cDNA was amplified by PCR. The amplified system included 5 μl of 10× PCR buffer, 1 μl of 10 mmol/L dNTP mix, 2 μl of 50 pmol/L sense and antisense primers respectively, 2 U Superscript TM -II polymerase, 1 μg cDNA and H 2 O to total 50 μl. PCR was performed typically with 28 cycles of 1 min denaturation at 94 o C, 1 min annealing at 58 o C and 1 min extension at 72 o C on a thermal cycler (Biometra). For amplification of variable domain via PCR with easy-A polymerase (Stratagene), the primers P ployC 5'-CCC CCC CCC CCC CCC-3' and V RACEHFOR 5'-ACT AGT ACA ATC CCC TGG GCA CAA T-3' flanking the heavy chain, and P ployC and V RACEκFOR 5'-CGT CAT GTC GAC GGA TCC AAG CTT CAA GAA GCA CAC GAC TGA GGC AC-3' were used, flanking the light chain. Amplified DNA was linked to pMD18-T vector (TaKaRa) and transformed into E. coli DH5α cells. Two independent clones of each variable domain were sequenced and compared for identity.
Tertiary structure prediction of ScFv 2E8 -C H 1-gp41
Based on the sequence of ScFv 2E8 , a C H 1 fragment from the hybridoma 2E8 (data unpublished) was cloned, and HIV-1 gp41 peptide sequence was searched from the published data. Three gene fragments (ScFv 2E8 /C H 1/HIV-1gp41) theoretically constructed the new recombinant gene ScFv 2E8 -C H 1-gp41. The sequence of ScFv 2E8 -C H 1-gp41 gene was submitted to SWISS-MODEL by ExPASy; templates were obtained by searching in the ExNRL-3D database (13, 14) . Using the reported structure of ScFv 2E8 , the tertiary structure of ScFv 2E8 -C H 1-gp41 was constructed.
pET-his-ScFv 2E8 -C H 1-gp41 plasmid construction ScFv gene was constructed by overlap extension PCR. A short peptide linker sequence (Gly 4 -Ser 1 ) 3 was inserted between V H and V L and formed V H -linker-V L orientation. The C H 1 fragment derived from mAb 2E8 was ligated at the 3' 
Constant region (C H 1)
GCC AAA ACG ACA CCC CCA TCT GTC TAT CCA CTG GCC CCT GGA TCT GCT GCC CAA ACT AAC TCC ATG GTG
2E8 V L -C L 1 (part) nucleotide and deduced amino acid sequence
Leader peptide
Constant region (C L 1) terminal of V L , and the conserved region sequence of HIV gp41 (the peptide sequence of HIV-1gp41-CGT ATC CTG GCC GTC GAA CGT TAT CTG AAA GAT CAG CAG CTG CTG GGC ATC TGG GGC TGC TCT GGC AAA CTG ATC TGC ACC ACG GCG GTC CCG TGG AAT GCG TCT) was ligated by multiple PCR at the 3' terminal of C H 1 fragment to construct recombinant ScFv 2E8 -C H 1-gp41 gene; and eight primers were used (Table 1) . Then the recombinant gene was linked to pMD18-T vector (pMD-18T-ScFv 2E8 -C H 1-gp41) and transformed into E. coli DH5α cells. Two independent clones were sequenced and compared for identity.
Expression and purification of ScFv 2E8 -C H 1-gp41
To express the ScFv 2E8 -C H 1-gp41 gene, the expression vector pET-his (Jingmei Biotech) was used to construct pET-hisScFv 2E8 -C H 1-gp41 and transformed into BL21(DE3)plysS of E. coli. The single colony of transformed E. coli was picked out and inoculated in a flask containing 20 ml of LB medium supplemented with ampicillin (150 mg/ml, 1% glucose) and cultivated at 30 o C 70-90 rpm for 10 h as the seed cells. On day 2, the seed cells were added into 200 ml of LB medium supplemented with ampicillin (150 mg/ml, 1% glucose), at 37 o C 300 rpm for 2 h until cell density OD 600 reached 0.6. The culture was induced by addition with IPTG at the final concentration of 100 μg/ml for 1. 
SDS-PAGE and Western blotting
For expression product analysis, the fusion protein was investigated through the 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Western blotting assay was performed with the anti-His antibody after the SDS-PAGE. All steps were performed according to manufacturer's instructions. About 30 μl of sample was run on 12% sodium dodecyl sulfate polyacrylamide gel for identifying fusion protein, the product of ScFv 2E8 -C H 1-gp41 gene. The separated proteins were transferred to nitrocellulose filter (Millipore HAWP) using buffer (25 mmol/L Tris-HCl pH 8.0, glycine, 20% methanol). In following washing procedure between every two steps, PBST was used three times for 5 min. The membranes were first blocked for 1 h with the blocking buffer, followed by adding HRPlabeled goat anti-mouse antibody, then incubated for another 1 h, and visualized by adding the combined substrate of H 2 O 2 and 4-chloro-1-naphthol.
Competitive ELISA assay
The broken membranes of RBCs were coated on each well of a 96-well plate. Renatured fusion protein (the concentration of 15-100 μg/ml) was added and incubated on the plate. After incubation, 10.5 μg/ml of mAb 2E8 was added. Unbound mAb 2E8 and fusion protein were removed by washing three times with assay buffer. An anti-mouse IgG-HRP conjugate was used to detect the bound mAb 2E8 . All the incubation steps were performed for 1 h at 37 o C. The reaction was developed using o-phenylenediamine (OPD) as a chromogenic substrate. Inhibition percentages were calculated as 1 -(A/B) × 100%, where A and B were the absorbance values at 492 nm for a given fusion protein concentration and no fusion protein added respectively.
Immunofluorescence
Human RBCs (7 × 10 7 , type O) and 500 μl of 0.9% saline were mixed together at room temperature in a reaction pipe. Fifty μl of fusion protein (0.4 mg/ml) was added into the reaction pipe and mixed gently. The reaction pipe was incubated for 30 min at 37 o C in all subsequent steps and RBCs were harvested by centrifugation at 3,500 rpm for 5 min at room temperature, resuspended in 500 μl of 0.9% saline twice between every two steps. Five μl of anti-His tag antibody was added to combine with the fusion protein and 5 μl of FITC-conjugated goat anti-mouse IgG antibody was added as the secondary antibody. When the RBCs combined the fusion protein with anti-His tag antibody and FITCconjugated goat anti-mouse IgG antibody completely, 10 μl of RBCs suspension was taken and observed under fluorescence microscope (Nikon UFX-II).
Bifunctional protein for haemagglutination
Quantitative microplate agglutination assay to detect anti-HIV antibodies in 30 plasma samples was carried out.
Human RBCs of type O RhD-negative blood were washed twice with 0.9% saline. To 3-5% RBC suspension, purified fusion protein was added to a final concentration of 1 μg/ml. Twenty μl of RBCs and 10 μl of positive plasma and 10 μl of fusion protein were added to a microplate respectively. The microplate was incubated at room temperature for 5 min and agglutination end point was recorded. (Figure 1 ).
Results
Construction of ScFv
For the construction of the bifunctional molecules, a multiple PCR was used to form the recombinant ScFv 2E8 -C H 1-gp41 gene containing the ScFv 2E8 fragment against H antigen on RBC and a conserved region sequence of HIV gp41 and the C H 1 fragment derived from the constant region of the mAb 2E8 . The agarose gel electrophoresis (AGE, 15 g/L) showed the PCR products in the assay of the amplification of ScFv 2E8 -C H 1-gp41 gene was 1,150 bp, which was definitely the same size as predicted. The successful construction of the pET-his-ScFv 2E8 -C H 1-gp41 plasmid was identified by the sequencing outcome (Figure 2 ). The three dimensional structure of ScFv 2E8 -C H 1-gp41 was predicted and depicted in Figure 3 .
Identification of bifunctional protein by SDS-PAGE and
Western blotting SDS-PAGE result showed that there was one more additional band in recombinant bacteria group than the control, which was just the same size (about 45 kDa) as predicted (Figure 4) . To purify recombinant fusion protein, bacteria were harvested and sonicated, and the cellular debris was removed by centrifugation at 4 o C. The supernatant applied to His-bind resin column and the eluent was dialyzed against refolding buffer I, then continued to dialyze against refolding buffer II. The final product was filtrated with 0.22 μm filter membrane and stored at 4 o C. After three times applying the His-bind resin column, a relatively purified protein was obtained ( Figure 5 ).
For improving the quantity of the target protein, a pET-his vector system was used to express the bifunctional protein in the form of inclusion bodies in periplasmic space, and obtain larger amount of concentrated fusion protein (2.5-3 g/L) by BCA (bicinchoninic acid, Bradford) method.
Western blotting identified a hybridization band which was found only in recombinant bacteria lane, and was not detected in control group (Figure 6 ). It suggested that the expressed product of recombinant bacteria was the target fusion protein.
Functional detection of the bifunctional protein
Competitive ELISA assay was performed to identify if mAb 2E8 and bifunctional protein bind the same epitope on the membrane of RBCs (Figure 7) . The result indicated that the bifunctional fusion protein as mentioned above kept the antigenic specificity of the native antibody since its binding to H antigen was inhibited by mAb 2E8 in a dose-dependent manner.
For visualizing demonstration of the binding of bifunctional protein with RBCs, an immunofluorescence microscopy was performed. Under the microscope the green fluorescence circling the RBC was observed and the formation of RBC was displayed. No green fluorescence was found in the control without adding anti-His tag antibody (Figure 8) .
Application of bifunctional protein in haemagglutination assay
Since fusion protein was designed for use in hemagglutination-based assay for detection of anti-HIV antibody, it was evaluated in a microtiter plate-based agglutination assay using 30 HIV positive samples (AIDS Test Center of PLA) that were confirmed by Western blotting. Twenty-two of 30 positive samples showed strong agglutination with fusion protein and 8 of 30 showed weak reactivity ( Figure 9 ). When increasing the quantity of the weak agglutination samples in the well, agglutination became stronger. It was possible that low titer of anti-gp41 antibodies in the samples might not be sufficient to produce strong agglutination of RBCs. Thirty antibody-negative samples (from The General Hospital of PLA) showed no agglutination with bifunctional protein (data not shown).
Discussion
We had designed and constructed a bacterial expression vector to produce a fusion protein of ScFv 2E8 -C H 1-gp41 bispecific molecule in E. coli. The fusion protein was purified to homogeneity and examined for antigen reactivity. Like the native mAb from which it was derived, the recombinant fusion protein showed binding activity and specificity for H antigen on erythrocyte. Meanwhile the fusion protein ScFv 2E8 -C H 1-gp41, as the main ingredient of reagent for autologous erythrocyte agglutination test, could agglutinate RBCs in the presence of HIV-1 gp41 antibodies using sera from HIV-infected individuals. The development of antibody engineering technology had allowed the modification of existing mouse mAbs into recombinant segments that kept high affinity and specificity. For this purpose, one of the first things was the construction of the recombinant smallest antibody fragment with antigen binding specificity, single-chain Fv. ScFv was composed of antibody heavy and light chain variable domains ligated by a short linker peptide (18) . Generally, the variable region genes of antibody were generated by PCR. Originally, the variable region gene cloning of antibody was performed by using mixtures of degenerate oligonucleotides. Although the degenerate oligonucleotide primers were designed to anneal to the conserved residues at the beginning of framework one, the use of degenerate oligonucleotides could produce sequencing mistakes because of the random mismatching (19) . As for the primers designed from the leader peptide sequence of antibodies might avoid random mismatching in the conserved region, the putative primers might not be consistent with that of the wild-type gene since the signal peptide were different in the sequence of antibodies (20) .
In this study, in order to make sure the integrity and accuracy of variable region, a 5' RACE method was used for the gene cloning from the mAb 2E8 (21) . In brief, the first strand cDNA were synthesized by reverse transcriptase from the total RNA, and a poly-G sequence was anchored at the 5' terminal of cDNA by terminal transferase. The variable region genes were amplified by PCR with a forward poly-C anchor primer and a reverse primer specific for constant region sequence. The amino aicd sequence of heavy and light chain and leader peptide were demonstrated to be correct by the analysis of Kabat data base.
Following the cloning of the V H and V L , an ScFv gene was constructed by overlap extension PCR in which the peptide linker between the V H and V L was encoded in the PCR primer. The flexible linker (Gly 4 Ser) 3 was used to link the two variable region fragment (V H and V L ) which was hydrophilic and could preclude interaction with the V-regions during folding (22) . Though ScFv had a lot of advantages in the immunological assays and therapeutic use sometimes, it would not be sufficient for target use in its unconjugated form. On the contrary, the form of ScFv fusion protein would be desired molecule for application. For example, recombinant immunoglobulin fragment linked to either C terminal immunoreactive peptide epitopes or a reported enzyme may be used as bifunctional diagnostic reagents (22) .
In our study, a C H 1 fragment derived from mAb 2E8 , as a spacer, between ScFV 2E8 and gp41 gene, was introduced at the 3' terminal of V L and could either enhance the stability of the fusion protein or separate the functional domain of HIV-1 gp41 from that of ScFv 2E8 in the space. Then, the conserved sequences of the HIV-1 gp41 gene were ligated at the 3' terminal of C H 1 fragment by multiple PCR. So the formation of ScFv fusion protein bears two kinds of different functions that it could bind the H antigen on RBCs with the domain of ScFv and react with anti-gp41 antibodies with gp41 peptide domain in the whole blood.
The development of methods for the expression of ScFv fusion protein in E. coli had offered a convenient way to produce the engineering antibodies. A number of different molecules had been expressed in E. coli in soluble form, though the yield was lower. A relatively fine approach to high level production of ScFv fusion protein relied on cytosolic expression as inclusion bodies followed by denaturation and in vitro renaturation procedure. In our study, a pET-his vector of E. coli was used to express our target protein (ScFv 2E8 -C H 1-gp41) in the form of inclusion bodies. In order to obtain high amounts of concentrated fusion protein for purification, a strategy of denaturation and renaturation was adapted (23) and a relatively good yield (2.5-3 g/L) was got.
Although it has been reported that ScFvs with V Hlinker-V L orientation could not be expressed (24, 25) , the bispecific molecule gene ScFv 2E8 -C H 1-gp41 containing V Hlinker-V L in the ScFv terminus of ScFv 2E8 -C H 1-gp41 was also produced in the bacterial expression system.
The immunoglobulin gene fragments could be engineered to contain C terminal polypeptide tails which permits easy detection and purification of the recombinant antibodies. In the present study, a His-tag was introduced into the ScFv 2E8 -C H 1-gp41 gene and formed two tags including the vector's His-tag at both the terminals of the recombinant gene, thereby facilitating the protein's recovery through nickel affinity chromatography and renaturation with GSH/ GSSH system (26) .
In this experiment, the positive sample had been confirmed by Western blotting. In China the HIV-1 was the majority type of HIV, and the gp41 peptide sequence was the main conserved region that triggered the immunological response in the human body. But the difference of individuals in the immune system gave rise to different titer response. The higher titer, the stronger agglutination reaction.
We successfully designed and prepared bifunctional fusion protein from inclusion bodies in E. coli, which had the capability of binding to both human RBCs and HIV-1 antibody. When anti-HIV-1 antibody was present in human blood specimens and the agglutination could be visualized with the naked eyes. Autologous red cell agglutination assay had the advantages of shorter detection time, simple procedure, no special equipment and direct-viewing results. The technology described in this paper could also be used to develop similar molecules for detection of various infections, such as hepatitis B, hepatitis C and syphilis, which were relevant in blood transfusion.
